Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Hoon Cho

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Scientific Reports|May 24, 2016
Suppression of 14-3-3γ-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cellsYoung-Sun Lee, Jae Kwang Lee, Yeonju Bae, et al.
Npj Drug Discovery|June 30, 2026
Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegenerationRebecca R Leahey, Martin Weber, Chang Hoon Cho, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2025
Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transectionSeong Kwon Hur, Rebecca R Leahey, Mitchell Geringer, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 3, 2024
Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple SclerosisAinhoa Etxeberria, Yun-An A Shen, Stephen Vito, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 1, 2024
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonismStephen P Schauer, Chang Hoon Cho, Gloriia Novikova, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Scientific Reports|May 24, 2016
Suppression of 14-3-3γ-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cellsYoung-Sun Lee, Jae Kwang Lee, Yeonju Bae, et al.
Npj Drug Discovery|June 30, 2026
Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegenerationRebecca R Leahey, Martin Weber, Chang Hoon Cho, et al.
Journal of Neuropathology and Experimental Neurology|June 6, 2025
Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transectionSeong Kwon Hur, Rebecca R Leahey, Mitchell Geringer, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 3, 2024
Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple SclerosisAinhoa Etxeberria, Yun-An A Shen, Stephen Vito, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 1, 2024
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonismStephen P Schauer, Chang Hoon Cho, Gloriia Novikova, et al.
Pageof 5